Increased risk of psoriasis with terbinafine, itraconazole

Increased risk of psoriasis with terbinafine, itraconazole Reactions 1680, p11 - 2 Dec 2017 Increased risk of psoriasis with terbinafine, itraconazole There is an increased risk of psoriasis in patients who have been exposed to the antifungal agents terbinafine or itraconazole, according to Taiwanese researchers. Researchers from the National Taiwan University utilised data from the National Health Insurance Research Database to identify patients with onychomycosis who had experienced cases of incident psoriasis during 2004 and 2010. A total of 3831 such patients were identified, as well as an identical number of matched controls. Compared with the matched controls, patients who had developed psoriasis were significantly more likely to have used terbinafine (>59%) or itraconazole (>42%). After adjusting for potential confounders and cumulative duration of antifungal drug prescription, use of terbinafine or itraconazole was associated with an increased risk of incident psoriasis (odds ratio [OR] 1.33; 95% CI 1.15, 1.54), and this association was found to be even stronger with more recent exposure to these drugs (OR 2.96; 95% CI 2.25, 3.90). Furthermore, when the individual drug risks were assessed, it was found that the risk of psoriasis was higher for itraconazole users, versus terbinafine users. The researchers highlighted that "future prospective studies should investigate if terbinafine or itraconazole use induces de novo psoriasis or aggravates pre-existing psoriasis, and if [the] psoriasis risk is lower for terbinafine than for itraconazole". They also noted that at present, the mechanisms via which itraconazole or terbinafine may cause psoriasis remain unclear. Chiu HY, et al. Risk of Psoriasis Following Terbinafine or Itraconazole Treatment for Onychomycosis: A Population-Based Case-Control Comparative Study. Drug Safety : 6 Nov 2017. Available from: URL: https://link.springer.com/ article/10.1007/s40264-017-0614-2 803284959 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Increased risk of psoriasis with terbinafine, itraconazole

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/increased-risk-of-psoriasis-with-terbinafine-itraconazole-lgzryzo5os
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38942-5
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p11 - 2 Dec 2017 Increased risk of psoriasis with terbinafine, itraconazole There is an increased risk of psoriasis in patients who have been exposed to the antifungal agents terbinafine or itraconazole, according to Taiwanese researchers. Researchers from the National Taiwan University utilised data from the National Health Insurance Research Database to identify patients with onychomycosis who had experienced cases of incident psoriasis during 2004 and 2010. A total of 3831 such patients were identified, as well as an identical number of matched controls. Compared with the matched controls, patients who had developed psoriasis were significantly more likely to have used terbinafine (>59%) or itraconazole (>42%). After adjusting for potential confounders and cumulative duration of antifungal drug prescription, use of terbinafine or itraconazole was associated with an increased risk of incident psoriasis (odds ratio [OR] 1.33; 95% CI 1.15, 1.54), and this association was found to be even stronger with more recent exposure to these drugs (OR 2.96; 95% CI 2.25, 3.90). Furthermore, when the individual drug risks were assessed, it was found that the risk of psoriasis was higher for itraconazole users, versus terbinafine users. The researchers highlighted that "future prospective studies should investigate if terbinafine or itraconazole use induces de novo psoriasis or aggravates pre-existing psoriasis, and if [the] psoriasis risk is lower for terbinafine than for itraconazole". They also noted that at present, the mechanisms via which itraconazole or terbinafine may cause psoriasis remain unclear. Chiu HY, et al. Risk of Psoriasis Following Terbinafine or Itraconazole Treatment for Onychomycosis: A Population-Based Case-Control Comparative Study. Drug Safety : 6 Nov 2017. Available from: URL: https://link.springer.com/ article/10.1007/s40264-017-0614-2 803284959 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off